By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Intarcia


Drug Discovery

Company News
Intarcia Submits New Drug Application (NDA) To FDA For U.S. Marketing Approval Of ITCA 650 In Type 2 Diabetes 11/21/2016 6:41:01 AM
Week In Review: China's Luxin Invests In $215 Million Funding For Intarcia's Long-Term Diabetes Device 9/19/2016 8:10:50 AM
Boston 'Unicorn' Intarcia Banks a Whopping $215 Million to Support Diabetes Drug Pump 9/16/2016 6:07:49 AM
Intarcia Completes First Close Of A Major Equity Financing; Poised For ITCA 650 NDA Filing For Type 2 Diabetes, Commercial Readiness And Pipeline Progression 9/15/2016 10:00:26 AM
Intarcia to Move HQ Next Month, Plans to Double Workforce By End of 2017 6/14/2016 9:01:13 AM
Intarcia Release: New NHANES Analysis Shows No Improvement In Last Decade To Get More Diabetes Patients To Hba1c Goal; Separate Study Suggests Reduced Efficacy In Real-World Plays Large Role Due To Adherence Falling Far Short Of Clinical Trials 6/13/2016 12:27:28 PM
Intarcia Presents FREEDOM-2 Trial Results In Type 2 Diabetes Demonstrating Clinically Meaningful Superiority And Sustained Glucose Control And Weight Reduction For ITCA 650 Vs. Januvia: Oral Presentation At American Diabetes Association 76th Scientific Sessions 6/13/2016 11:43:41 AM
Intarcia Announces Branding Of The Medici Drug Delivery System -- A Platform Of Technologies Key To Advancing Its Pipeline Of Once-Yearly Peptide And Antibody Fragment-Based Therapeutics In Poorly Controlled Chronic Diseases 6/7/2016 11:02:58 AM
Intarcia And Numab AG Announce Achievement Of Key Research And Development Milestones 6/2/2016 9:45:00 AM
Intarcia Touts Large Phase III Trial Diabetes Data, Bags $75 Million 5/6/2016 10:19:38 AM